

सं./ 31026/46/2020-Policy (E-14241)
भारत सरकार / Government of India
रसायन और उर्वरक मंत्रालय / Ministry of Chemicals and Fertilizers
औषध विभाग / Department of Pharmaceuticals

कर्तव्य भवन-2, नई दिल्ली 110001
Kartavya Bhawan-2, New Delhi-110001
Dated 14 October, 2026

OFFICE MEMORANDUM

Subject: Representation regarding adequate allocation and expeditious release of funds under the Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS) to pharmaceutical MSME units – reg.

The undersigned is directed to refer to your representation dated 31.07.2026 on the subject cited above and to inform that the issues raised therein have been examined in accordance with the guidelines (copy enclosed) of the Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS).

2. As per the guidelines of RPTUAS, pharmaceutical manufacturing units having an average turnover of less than Rs. 500 crore during the preceding three years are eligible for assistance under the Scheme, subject to fulfilment of the prescribed eligibility conditions. The incentive (maximum of Rs. 2.00 crore) is linked to investment in eligible activities and is detailed below:

- (i) Turnover from Rs. 1.00 crore to less than Rs. 50.00 crore:- 20% of investment under eligible activities;
- (ii) Turnover from Rs. 50.00 crore to less than Rs. 250.00 crore:- 15% of investment under eligible activities;
- (iii) Turnover from Rs. 250.00 crore to less than Rs. 500.00 crore:- 10% of investment under eligible activities;

3. The Scheme provides for a defined process for processing applications, which includes submission of gap analysis by the applicant, its examination by the Project Management Consultant (PMC) i.e. SIDBI, recommendation of eligible proposals to the Scheme Steering Committee (SSC), verification of eligible expenditure and release of incentive in prescribed instalments. Release of incentive is subject to submission and verification of the requisite Revised Schedule M/WHO-GMP certificates, and CA-certified expenditure prescribed under the Scheme. The prescribed timelines for release of the instalments are also provided in the Scheme guidelines.

4. The incentive approved under the Scheme is released by the Department of Pharmaceuticals, on the recommendation of the SSC, directly into the bank account of the approved beneficiary. The PMC undertakes verification of eligible expenditure and the relevant certificates/documents in accordance with the Scheme guidelines.


5. The concerns raised by FOPE regarding pending applications and expeditious release of assistance have been noted. It is reiterated that applications under the RPTUAS are processed in accordance with the approved Scheme guidelines and the prescribed procedure, subject to fulfilment of eligibility requirements and availability of

funds. Accordingly, as regards the progress of the RPTUAS Sub-Scheme, upto September, 2026, the Scheme Steering Committee (SSC) has approved 301 applications/pharmaceutical units for incentives amounting to approximately 300.48 crore for achieving Revised Schedule M/WHO GMP Certifications on their technology upgradation, which is nearly equivalent to the total outlay of the sub-scheme.

6. Out of the 301 approved applicants/pharmaceutical units, 157 applicants have upgraded their pharmaceutical manufacturing units and obtained certificates of compliance with the revised Schedule M and WHO GMP; another 17 applicants have reported completing technology upgrade of their pharmaceutical manufacturing units and applied for the said certifications; and a further 13 applicants have reported that they have completed their upgrade project and are in process of applying to the State Licensing Authority for the said certifications; and in 110 pharmaceutical units the projects are under implementation and the sanction of 04 pharmaceutical units were cancelled by the SSC.

Further, claims in respect of 134 pharmaceutical units, amounting to Rs. 103.98 crore, have been approved after submission of the Revised Schedule M/WHO-GMP certificates and verification of their authenticity from the concerned State Drug Controllers.

7. In view of above, FOPE is requested to advise its member units for timely submission of complete documents and fulfilment of the prescribed requirements so that eligible applications may be processed expeditiously.


(धर्मेन्द्र कुमार यादव) (Dharmendra Kumar Yadav)
अवर सचिव, भारत सरकार
Under Secretary to the Government of India
दूरभाष/ Tel.: 011 23071162
Email: US-PharmaPolicy@pharma-ept.gov.in

To

Shri Harish K. Jain,
National President
Federation of Pharma Entrepreneurs (FOPE),
301, 3rd Floor, Palm Court, Sector-16,
Gurugram – 122007.
Tele. No.: 0124-4069864
Email: info@fopeindia.com

Copy to:

Sh. Sunil Kumar Pandey, Under Secretary, Prime Minister's Office, Seva Teerth, New Delhi – 110 011 in response to PMO ID No. 6099006/PMO/2026/AR dated 07.09.2026.